

**MINISTRY OF CHEMICALS AND FERTILISERS**

## DEMAND NO. 7

**Department of Pharmaceuticals***(In ₹ crores)*

	Actual 2022-2023			Budget 2023-2024			Revised 2023-2024			Budget 2024-2025		
	Revenue	Capital	Total	Revenue	Capital	Total	Revenue	Capital	Total	Revenue	Capital	Total
Gross	2044.84	5.26	2050.10	3158.87	1.19	3160.06	2761.22	0.98	2762.20	4088.69	1.26	4089.95
Recoveries	-0.03	...	-0.03	...	...	...	...	...	...	...	...	...
Receipts	...	...	...	...	...	...	-64.25	...	-64.25	...	...	...
<b>Net</b>	<b>2044.81</b>	<b>5.26</b>	<b>2050.07</b>	<b>3158.87</b>	<b>1.19</b>	<b>3160.06</b>	<b>2696.97</b>	<b>0.98</b>	<b>2697.95</b>	<b>4088.69</b>	<b>1.26</b>	<b>4089.95</b>
A. The Budget allocations, net of recoveries and receipts, are given below:												
<b>CENTRE'S EXPENDITURE</b>												
<b>Establishment Expenditure of the Centre</b>												
1. Secretariat	17.00	...	17.00	20.37	0.73	21.10	19.14	0.60	19.74	20.58	0.80	21.38
2. National Pharmaceutical Pricing Authority (NPPA)	15.99	...	15.99	18.50	0.40	18.90	17.63	0.37	18.00	19.60	0.40	20.00
<b>Total-Establishment Expenditure of the Centre</b>	<b>32.99</b>	<b>...</b>	<b>32.99</b>	<b>38.87</b>	<b>1.13</b>	<b>40.00</b>	<b>36.77</b>	<b>0.97</b>	<b>37.74</b>	<b>40.18</b>	<b>1.20</b>	<b>41.38</b>
<b>Central Sector Schemes/Projects</b>												
3. National Institutes of Pharmaceutical Education and Research (NIPERs)	396.43	...	396.43	550.00	...	550.00	228.80	...	228.80	242.00	...	242.00
4. Jan Aushadhi Scheme	100.00	...	100.00	115.00	...	115.00	110.00	...	110.00	284.50	...	284.50
5. Development of Pharmaceutical Industry	31.02	...	31.02	...	...	...	...	...	...	...	...	...
6. Consumer Awareness Publicity and Price Monitoring	2.20	...	2.20	5.00	...	5.00	3.00	...	3.00	4.00	...	4.00
<b>Development of Pharmaceutical Industry</b>												
7. <i>Development of Pharmaceutical Industry</i>												
7.01 Pharmaceutical Promotion & Development Scheme (PPDS)	0.68	...	0.68	4.00	...	4.00	7.00	...	7.00	5.00	...	5.00
7.02 Assistance to Pharmaceutical Industry for Common Facilities (API-CF)/Cluster Development	...	...	...	51.00	...	51.00	44.50	...	44.50	50.00	...	50.00
7.03 Pharmaceuticals Technology Upgradation Assistance Scheme (PTUAS)	...	...	...	95.00	...	95.00	0.02	...	0.02	5.00	...	5.00
7.04 Promotion of Bulk Drug Parks	...	...	...	900.00	...	900.00	85.15	...	85.15	1000.00	...	1000.00
7.05 Promotion of Medical Device Parks	...	...	...	200.00	...	200.00	64.00	...	64.00	150.00	...	150.00
7.06 Human Resource Development in Medical Devices Sector	...	...	...	...	...	...	31.00	...	31.00	50.00	...	50.00
7.07 Assistance to Medical Device Clusters for Common Facilities (AMD-CF)	...	...	...	...	...	...	33.00	...	33.00	40.00	...	40.00
<b>Total- Development of Pharmaceutical Industry</b>	<b>0.68</b>	<b>...</b>	<b>0.68</b>	<b>1250.00</b>	<b>...</b>	<b>1250.00</b>	<b>264.67</b>	<b>...</b>	<b>264.67</b>	<b>1300.00</b>	<b>...</b>	<b>1300.00</b>

(In ₹ crores)

	Actual 2022-2023			Budget 2023-2024			Revised 2023-2024			Budget 2024-2025		
	Revenue	Capital	Total	Revenue	Capital	Total	Revenue	Capital	Total	Revenue	Capital	Total
<b>Production Linked Incentive Schemes</b>												
8. Production Linked Incentive Schemes												
8.01 Promotion of Bulk Drug Parks	751.49	...	751.49	...	...	...	...	...	...	...	...	...
8.02 Production Linked Incentive(PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials(KSMs)/Drug Intermediates(DIs) and Active Pharmaceutical Ingredients(APIs) in India	5.95	...	5.95	100.00	...	100.00	16.13	...	16.13	58.00	...	58.00
8.03 Promotion of Medical Device Parks	0.90	...	0.90	...	...	...	...	...	...	...	...	...
8.04 Production Linked Incentive (PLI) Scheme for Domestic Manufacturing of Medical Devices	11.50	...	11.50	100.00	...	100.00	48.16	...	48.16	85.00	...	85.00
8.05 Production Linked Incentive Scheme for Pharmaceuticals	655.15	...	655.15	1000.00	...	1000.00	1632.00	...	1632.00	2000.00	...	2000.00
Total- Production Linked Incentive Schemes	1424.99	...	1424.99	1200.00	...	1200.00	1696.29	...	1696.29	2143.00	...	2143.00
9. Promotion of Research and Innovation in Pharma Med-Tech (PRIP)	...	...	...	...	...	...	1.00	...	1.00	75.00	...	75.00
<b>Total-Central Sector Schemes/Projects</b>	<b>1955.32</b>	<b>...</b>	<b>1955.32</b>	<b>3120.00</b>	<b>...</b>	<b>3120.00</b>	<b>2303.76</b>	<b>...</b>	<b>2303.76</b>	<b>4048.50</b>	<b>...</b>	<b>4048.50</b>
<b>Other Central Sector Expenditure</b>												
<b>Autonomous Bodies</b>												
10. National Institute of Pharmaceutical Education and Research(NIPERs)	54.70	...	54.70	...	...	...	...	...	...	...	...	...
<b>Public Sector Undertakings</b>												
11. Assistance to PSUs	1.80	5.26	7.06	...	0.06	0.06	356.44	0.01	356.45	0.01	0.06	0.07
12. Write Off/Waiver of loans in respect of Pharmaceuticals PSUs												
12.01 Rajasthan Drugs and Pharmaceuticals Ltd. (RDPL)	...	...	...	...	...	...	64.25	...	64.25	...	...	...
	...	...	...	...	...	...	-64.25	...	-64.25	...	...	...
<i>Net</i>	...	...	...	...	...	...	...	...	...	...	...	...
<b>Total-Public Sector Undertakings</b>	<b>1.80</b>	<b>5.26</b>	<b>7.06</b>	<b>...</b>	<b>0.06</b>	<b>0.06</b>	<b>356.44</b>	<b>0.01</b>	<b>356.45</b>	<b>0.01</b>	<b>0.06</b>	<b>0.07</b>
<b>Total-Other Central Sector Expenditure</b>	<b>56.50</b>	<b>5.26</b>	<b>61.76</b>	<b>...</b>	<b>0.06</b>	<b>0.06</b>	<b>356.44</b>	<b>0.01</b>	<b>356.45</b>	<b>0.01</b>	<b>0.06</b>	<b>0.07</b>
<b>Grand Total</b>	<b>2044.81</b>	<b>5.26</b>	<b>2050.07</b>	<b>3158.87</b>	<b>1.19</b>	<b>3160.06</b>	<b>2696.97</b>	<b>0.98</b>	<b>2697.95</b>	<b>4088.69</b>	<b>1.26</b>	<b>4089.95</b>
<b>B. Developmental Heads</b>												
<b>Economic Services</b>												
1. Industries	2027.81	...	2027.81	3077.00	...	3077.00	2643.95	...	2643.95	4015.46	...	4015.46
2. Secretariat-Economic Services	17.00	...	17.00	20.37	...	20.37	19.14	...	19.14	20.58	...	20.58
3. Capital Outlay on Chemical and Pharmaceutical Industries	...	...	...	...	...	...	...	0.01	0.01	...	...	...
4. Capital Outlay on Other General Economic Services	...	...	...	...	1.13	1.13	...	0.97	0.97	...	1.20	1.20

(In ₹ crores)

	Actual 2022-2023			Budget 2023-2024			Revised 2023-2024			Budget 2024-2025		
	Revenue	Capital	Total	Revenue	Capital	Total	Revenue	Capital	Total	Revenue	Capital	Total
5. Loans for Chemical and Pharmaceutical Industries	...	5.26	5.26	...	0.06	0.06	...	...	...	...	0.06	0.06
<b>Total-Economic Services Others</b>	<b>2044.81</b>	<b>5.26</b>	<b>2050.07</b>	<b>3097.37</b>	<b>1.19</b>	<b>3098.56</b>	<b>2663.09</b>	<b>0.98</b>	<b>2664.07</b>	<b>4036.04</b>	<b>1.26</b>	<b>4037.30</b>
6. North Eastern Areas	...	...	...	61.50	...	61.50	33.88	...	33.88	52.65	...	52.65
<b>Total-Others</b>	<b>...</b>	<b>...</b>	<b>...</b>	<b>61.50</b>	<b>...</b>	<b>61.50</b>	<b>33.88</b>	<b>...</b>	<b>33.88</b>	<b>52.65</b>	<b>...</b>	<b>52.65</b>
<b>Grand Total</b>	<b>2044.81</b>	<b>5.26</b>	<b>2050.07</b>	<b>3158.87</b>	<b>1.19</b>	<b>3160.06</b>	<b>2696.97</b>	<b>0.98</b>	<b>2697.95</b>	<b>4088.69</b>	<b>1.26</b>	<b>4089.95</b>
	Budget Support	IEBR	Total	Budget Support	IEBR	Total	Budget Support	IEBR	Total	Budget Support	IEBR	Total
<b>C. Investment in Public Enterprises</b>												
1. Karnataka Antibiotics and Pharmaceuticals Ltd	...	24.88	24.88	...	32.00	32.00	...	32.00	32.00	...	12.00	12.00
2. Indian Drugs and Pharmaceuticals Ltd	4.00	...	4.00	0.01	...	0.01	...	...	...	0.01	...	0.01
3. Hindustan Antibiotics Ltd	1.26	...	1.26	0.01	111.50	111.51	...	...	...	0.01	...	0.01
4. Bengal Chemicals and Pharmaceuticals Ltd	...	...	...	0.01	...	0.01	...	...	...	0.01	...	0.01
5. Bengal Immunity Ltd	...	...	...	0.01	...	0.01	...	...	...	0.01	...	0.01
6. Rajasthan Drugs and Pharmaceuticals Ltd	...	...	...	0.01	...	0.01	...	...	...	0.01	...	0.01
7. Smith Stanistreet Pharmaceuticals Ltd	...	...	...	0.01	...	0.01	...	...	...	0.01	...	0.01
<b>Total</b>	<b>5.26</b>	<b>24.88</b>	<b>30.14</b>	<b>0.06</b>	<b>143.50</b>	<b>143.56</b>	<b>...</b>	<b>32.00</b>	<b>32.00</b>	<b>0.06</b>	<b>12.00</b>	<b>12.06</b>

1. **Secretariat:** The provision is for the Salary and Establishment Expenditure of Department of Pharmaceuticals.

2. **National Pharmaceutical Pricing Authority (NPPA):** The provision is for the Secretariat and Establishment Expenditure of NPPA,

3. **National Institutes of Pharmaceutical Education and Research (NIPERs):** The provision is made for 7 NIPERs i.e. Mohali, Ahmedabad, Guwahati, Hajipur, Hyderabad, Kolkata and Rae Bareli for incurring salary of employees, establishment and other expenditure.

4. **Jan Aushadhi Scheme:** Under the Jan Aushadhi Scheme for effective implementation of Pradhan Mantri Bhartiya Janaushadhi Pariyojana(PMBJP).

6. **Consumer Awareness Publicity and Price Monitoring:** The provision is for Consumer Awareness, Publicity and providing support to State resource units.

7.01. **Pharmaceutical Promotion & Development Scheme(PPDS):** The provision for promotion, development and export promotion in Pharmaceuticals sector by extending financial support for conduct of seminars, conferences, exhibitions, mounting delegation to and from India for promotion of exports as well as investments, conduction studies/ consultancies for facilitating growth, export as well as critical issues affecting Pharma Sector.

7.02. **Assistance to Pharmaceutical Industry for Common Facilities(API-CF)/Cluster Development:** The Scheme would be implemented in a Public Private Partnership (PPP) mode through one time grant-in-aid to be released in various phases for creation of identified infrastructure and common facilities to a Special Purpose Vehicles (SPVs) set up for the purpose.

7.03. **Pharmaceuticals Technology Upgradation Assistance Scheme(PTUAS):** The sub-scheme is aimed at providing interest subvention to the eligible Small and Medium Scale Pharma Units having GMP compliant manufacturing facilities both for Bulk Drugs and Pharmaceuticals formulations. The eligible units intending to upgrade their manufacturing infrastructure to attain WHO-GMP norms, have to secure loan from any Financial Institution for upgrading their infrastructure and technology.

7.04. **Promotion of Bulk Drug Parks:** To promote setting up of bulk drug parks in the country for providing easy access to world class Common Infrastructure Facilities (CIF) to bulk drug units located in the park in order to significantly bring down the manufacturing cost of bulk drugs and thereby make India self-reliant in bulk drugs by increasing the competitiveness of the domestic bulk drug industry.

7.05. **Promotion of Medical Device Parks:** Creation of world class infrastructure facilities in order to make Indian medical device industry a global leader. Easy access to standard testing and infrastructure facilities through creation of world class Common Infrastructure Facilities for increased competitiveness will result in significant reduction of the cost of production of medical devices leading to better availability and affordability of medical devices in the domestic market.

7.06. **Human Resource Development in Medical Devices Sector:** The objective of the scheme is to fill the gap existing in the education and research in medical devices sector and to ensure quality teaching, training and nurturing excellence in Medical Technology education for generating critical mass of trained human resource to meet the requirements of rapidly innovating multidisciplinary areas of Medical Technology and create R&D ecosystem for the sector.

7.07. **Assistance to Medical Device Clusters for Common Facilities (AMD-CF):** The scheme aims to strengthen Medical Device clusters by providing financial assistance and to strengthen and / or establish more Testing Laboratories for Medical Devices to improve quality and sustainable growth.

8.02. **Production Linked Incentive(PLI) Scheme for Promotion of Domestic Manufacturing of Critical Key Starting Materials(KSMs)/Drug Intermediates(DIs) and Active Pharmaceutical Ingredients(APIs) in India:** The objective of the scheme is to attain self-reliance and reduce import dependence in critical KSMs/DIs/APIs. Under the scheme, financial incentives shall be given based on committed investment and sales made by selected applicant for the eligible products.

8.04. **Production Linked Incentive (PLI) Scheme for Domestic Manufacturing of Medical Devices:** The scheme proposes a financial incentive to boost domestic manufacturing and attract large investment in the Medical Device Sector.

8.05. **Production Linked Incentive Scheme for Pharmaceuticals:** The objective of the scheme is to enhance India manufacturing capabilities by increasing investment and production in the sector and contributing to product diversification to high value goods in the pharmaceutical sector.

9. **Promotion of Research and Innovation in Pharma Med-Tech (PRIP):** The objective of the scheme is to encourage industry to invest in Rand D in Priority areas and to inculcate the culture of quality research and nurture the pool of scientists in the country by promoting industry-academia linkage, which will lead to sustained global competitive advantage and contribute to quality employment generation in the country

11. **Assistance to PSUs:** These are provisions under loan kept for the 6 Pharmaceuticals Public Sector Undertakings(PSUs).

12. **Write Off/Waiver of loans in respect of Pharmaceuticals PSUs:** A loan amount of ₹64.25 crore has been waived off in respect of RDPL.